162 related articles for article (PubMed ID: 15222676)
1. Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.
De Shong D; Mathis AS
Pharmacotherapy; 2004 Jun; 24(6):819-20; author reply 820. PubMed ID: 15222676
[No Abstract] [Full Text] [Related]
2. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Walker PD; Brokering KL; Theobald JC
Pharmacotherapy; 2003 Dec; 23(12):1617-26. PubMed ID: 14695041
[TBL] [Abstract][Full Text] [Related]
3. Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis.
Naeem M; McEnteggart GE; Murphy TP; Prince E; Ahn S; Soares G
Clin Imaging; 2015; 39(5):759-64. PubMed ID: 25709111
[TBL] [Abstract][Full Text] [Related]
4. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
5. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
Kini AS; Mitre CA; Kamran M; Suleman J; Kim M; Duffy ME; Marmur JD; Sharma SK
Am J Cardiol; 2002 Apr; 89(8):999-1002. PubMed ID: 11950448
[No Abstract] [Full Text] [Related]
6. Preventing contrast-induced nephropathy with fenoldopam.
Hunter DW; Chamsuddin A; Bjarnason H; Kowalik K
Tech Vasc Interv Radiol; 2001 Mar; 4(1):53-6. PubMed ID: 11981789
[TBL] [Abstract][Full Text] [Related]
7. Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series.
Madyoon H; Croushore L
J Interv Cardiol; 2001 Apr; 14(2):179-85. PubMed ID: 12053301
[TBL] [Abstract][Full Text] [Related]
8. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
[TBL] [Abstract][Full Text] [Related]
9. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
Lepor NE
Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733
[TBL] [Abstract][Full Text] [Related]
10. Contrast-induced nephropathy remains a serious complication of PCI.
Mehran R
J Interv Cardiol; 2007 Jun; 20(3):236-40. PubMed ID: 17524117
[No Abstract] [Full Text] [Related]
11. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
Chamsuddin AA; Kowalik KJ; Bjarnason H; Dietz CA; Rosenberg MS; Gomes MD; McDermott CM; Hunter DW
AJR Am J Roentgenol; 2002 Sep; 179(3):591-6. PubMed ID: 12185025
[TBL] [Abstract][Full Text] [Related]
12. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
Kini AS; Mitre CA; Kim M; Kamran M; Reich D; Sharma SK
Catheter Cardiovasc Interv; 2002 Feb; 55(2):169-73. PubMed ID: 11835641
[TBL] [Abstract][Full Text] [Related]
13. Contrast-induced nephropathy.
Rundback JH; Nahl D; Yoo V
J Vasc Surg; 2011 Aug; 54(2):575-9. PubMed ID: 21741789
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
15. The third strike.
Brinker JA
Catheter Cardiovasc Interv; 2002 Nov; 57(3):284-5. PubMed ID: 12410498
[No Abstract] [Full Text] [Related]
16. Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.
van den Berk G; Tonino S; de Fijter C; Smit W; Schultz MJ
Crit Care; 2005 Aug; 9(4):361-70. PubMed ID: 16137385
[TBL] [Abstract][Full Text] [Related]
17. Contrast-induced nephropathy: protective role of fenoldopam.
Caixeta A; Dogan O; Weisz G
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
[TBL] [Abstract][Full Text] [Related]
18. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
Tumlin JA; Wang A; Murray PT; Mathur VS
Am Heart J; 2002 May; 143(5):894-903. PubMed ID: 12040355
[TBL] [Abstract][Full Text] [Related]
19. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Asif A; Epstein DL; Epstein M
J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304
[TBL] [Abstract][Full Text] [Related]
20. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
